Clinical Trials

726 enrolled

Stomach Neoplasms

NCT07217704 2026-03-16

FAPI-GO

200 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT03221426 2026-03-09

KEYNOTE-585

Phase 3 Completed

1,007 enrolled 25 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT06346392 2026-03-09

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

572 enrolled

Stomach Neoplasms

NCT05871099 2026-03-06

Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not

616 enrolled

Stomach Neoplasms

NCT05568095 2026-03-04

STAR-221

1,040 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06346197 2026-03-02

CIME

132 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT05152147 2026-02-27

HERIZON-GEA-01

920 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

550 enrolled

Stomach Neoplasms

NCT07437573 2026-02-27

KLASS-09

Phase 3 Completed

94 enrolled

Stomach Neoplasms

NCT07431281 2026-02-24

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

2,130 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05052801 2026-02-19

FORTITUDE-101

547 enrolled

Stomach Neoplasms

NCT03504397 2026-02-13

Spotlight

565 enrolled 63 charts 1 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03653507 2026-02-06

GLOW

507 enrolled 65 charts 1 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04871412 2026-01-30

POISE

20 enrolled

GastrointestinalThoracic

Psychological Well-Being, Esophageal Neoplasms, Lung Neoplasms, Motor Activity, Stomach Neoplasms

NCT03399110 2026-01-27

XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)

1,024 enrolled

Stomach Neoplasms

NCT07366528 2026-01-26

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

387 enrolled

Neoplasms, Stomach Neoplasms

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

555 enrolled

Stomach Neoplasms

NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

550 enrolled

Stomach Neoplasms

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

490 enrolled

Phase 3 Not yet recruiting

Adenocarcinoma, Stomach Neoplasms

NCT07331454 2026-01-12

Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer

335 enrolled

Phase 3 Not yet recruiting

Stomach Neoplasms

NCT07314203 2026-01-02

SOP-XH-IRB

118 enrolled

Stomach Neoplasms

NCT07304271 2025-12-26

IPa-Gastric

262 enrolled

Stomach Neoplasms

NCT03042169 2025-12-23

SURGIGAST

Phase 3 Terminated

6 enrolled